Drugs and Devices

FDA approves new product to treat hereditary angioedema

On July 16, the U.S. Food and Drug Administration (FDA) approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema.
Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares